Lung cancer (small-cell) - topotecan (TA184)
Fast, easy summary view of NICE guidance on 'lung cancer'
Specific, concise statements that act as markers of high-quality, cost-effective patient care
Oral topotecan is recommended as a possible treatment for people with relapsed small-cell lung cancer if:
- re-treatment with the previous treatment is not considered appropriate and
- there is a medical reason why they cannot take the combination of cyclophosphamide, doxorubicin and vincristine (CAV).
Intravenous topotecan is not recommended for people with relapsed small-cell lung cancer.
Healthcare professionals should not stop prescribing topotecan for people with relapsed small-cell lung cancer who were already taking it when the guidance was issued. These people should be able to carry on taking topotecan until they and their specialist decide that it is the right time to stop treatment.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: lung cancer
This page was last updated: 08 May 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA184 Topotecan i drin canser yr ysgyfaint celloedd bach ar ôl ailwaelu: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.